Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension

Journal of Physiology

Volumn 589, Issue 1, 2011, Pages 207-219

  Honetschlägerová, Zuzana ^a,b   Husková, Zuzana ^a,b   Vaňourková, Zdeňka ^a,b   Sporková, Alexandra ^a,b   Kramer, Herbert J ^c   Hwang, Sung Hee ^d   Tsai, Hsing Ju ^d   Hammock, Bruce D ^d   Imig, John D ^e   Červenka, Luděk ^a,f   Kopkan, Libor ^a,b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b Center for Cardiovascular Research   (Czech Republic)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; 4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEXYLOXY]BENZOIC ACID; ANGIOTENSIN II; DRINKING WATER; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; RENIN; SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; ENZYME INHIBITION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; MALIGNANT HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; TRANSGENIC RAT; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARACHIDONIC ACIDS; BENZOIC ACIDS; BLOOD PRESSURE; CYTOCHROME P-450 CYP1A1; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; GLOMERULAR FILTRATION RATE; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; KIDNEY; MALE; MICE; PROMOTER REGIONS, GENETIC; PROTEINURIA; RATS; RENAL PLASMA FLOW; RENIN; SODIUM; TIME FACTORS; UREA;

EID: 78650367090     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2010.199505     Document Type: Article

References (47)

1. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY & Zhu Y (2007). Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 104, 9018-9023.
2. Campbell DJ, Karam H, Ménard J, Bruneval P & Mullins JJ (2009). Prorenin contributes to angiotensin peptide formation in transgenic rats with rat prorenin expression targeted to the liver. Hypertension 54, 1248-1253.
3. Capdevila JH, Falck JR & Imig JD (2007). Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int 72, 683-689.
4. Cervenka L, Wang CT & Navar LG (1998). Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats. Am J Physiol Renal Physiol 274, F940-E945.
5. Chábová VC, Kramer HJ, Vanecková I, Vernerová Z, Eis V, Tesar V, Skaroupková P, Thumová M, Schejbalová S, Husková Z, Vanourková Z, Kolskỳ A, Imig JD & Cervenka L (2007). Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol 47, 145-159.
6. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD & Imig JD (2005). An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46, 842-848.
7. Dos Santos EA, Dahly-Vernon AJ, Hoagland KM & Roman RJ (2004). Inhibition of the formation of EETs and 20-HETE with 1-aminobenzotriazole attenuates pressure-natriuresis. Am J Physiol Regul Integr Comp Physiol 287, R58-R68.
8. Drummond GB (2009). Reporting ethical matters in The Journal of Physiology: standards and advice. J Physiol 587, 713-719.
9. Erbanová M, Thumová M, Husková Z, Vanecková I, Vanourková Z, Mullins JJ, Kramer HJ, Bürgelová M, Rakusan D & Cervenka L (2009). Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens 27, 575-586.
10. Fleming I (2001). Cytochrome P450 and vascular homeostasis. Circ Res 89, 753-762.
11. Graciano ML, Mouton CR, Patterson ME, Seth DM, Mullins JJ & Mitchell KD (2007). Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 292, F1858-F1866.
12. Hall JE, Guyton AC, Smith MJ Jr & Coleman TG (1980). Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am J Physiol Renal Physiol 239, F271-F280.
13. Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, da Costa Goncalves ACh, Huang Y, Luft FC & Gollasch M (2009). Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 29, 54-60.
14. Huang H, Morisseau C, Wang J, Yang T, Falck JR, Hammock BD & Wang MH (2007). Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol 293, F342-F349.
15. Husková Z, Vanourková Z, Erbanová M, Thumová M, Opocenskỳ M, Mullins JJ, Kramer HJ, Bürgelová M & Cervenka L (2010). Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens 28, 495-509.
16. Hwang SH, Tsai HJ, Liu JY, Morisseau C & Hammock BD (2007). Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50, 3825-3840.
17. Imig JD & Hammock BD (2009). Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8, 794-805.
18. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T & Hammock BD (2005). An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46, 975-981.
19. Imig JD (2005). Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289, F496-F503.
20. Imig JD (2006). Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev 24, 169-188.
21. Imig JD (2009). Adenosine2A receptors and epoxyeicosatrienoic acids: a recipe for salt and blood pressure regulation. Hypertension 54, 1223-1225.
22. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL & Hammock BD (2007). Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82, 42-49.
23. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ & Bradlow HL (1993). Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 45, 1129-1136.
24. Jiang JG, Chen RJ, Xiao B, Yang S, Wang JN, Wang Y, Cowart LA, Xiao X, Wang DW & Xia Y (2007). Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 82, 162-174.
25. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R & Fleming I (2005). Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45, 759-765.
26. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGrath I, Kotelevtsev Y & Mullins JJ (2001). Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 276, 36727-36733.
27. Kopkan L, Kramer HJ, Husková Z, Vanourková Z, Skaroupková P, Thurmová M & Cervenka L (2005). The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J Hypertens 23, 1531-1539.
28. Kopkan L & Majid DS (2005). Superoxide contributes to development of salt sensitivity and hypertension induced by nitric oxide deficiency. Hypertension 46, 1026-1031.
29. Loch D, Hoey A, Morisseau C, Hammock BO & Brown L (2007). Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47, 87-98.
30. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD & Imig JD (2009). Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297, F740-F748.
31. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM & Mullins JJ (2006). Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin Angiotensin Aldosterone Syst 7, 74-86.
32. Mitchell KD & Mullins JJ (2005) Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 289, F1210-F1216.
33. Navar LG & Nishiyama A (2004). Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens 13, 107-115.
34. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM & Mitchell KD (1996). Paracrine regulation of the renal microcirculation. Physiol Rev 76, 425-536.
35. Ortiz RM, Graciano ML, Mullins JJ & Mitchell KD (2007). Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension in Cyp1a1-Ren2 transgenic rats. Am J Physiol Renal Physiol 293, F1584-F1591.
36. Oyekan AO, Youseff T, Fulton D, Quilley J & McGiff JC (1999). Renal cytochrome P450 ω-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest 104, 1131-1137.
37. Roman RJ (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82, 131-185.
38. Sakairi Y, Jacobson HR, Noland TD, Capdevila JH, Falck JR & Breyer MD (1995). 5, 6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am J Physiol Renal Physiol 268, F931-F939.
39. Satoh T, Cohen HT & Katz AI (1993). Intracellular signaling in the regulation of renal Na-K-ATPase. II. Role of eicosanoids. J Clin Invest 91, 409-415.
40. Sun P, Lin DH, Wang T, Babilonia E, Wang Z, Jin Y, Kemp R, Nasjletti A & Wang WH (2006). Low Na intake suppresses expression of CYP2C23 and arachidonic acid-induced inhibition of ENaC. Am J Physiol Renal Physiol 291, F1192-F1200.
41. Vanecková I, Kopkan L, Husková Z, Vanourková Z, Schejbalová S, Cervenka L & Kramer HJ (2007). Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade. Kidney Blood Press Res 30, 38-44.
42. Vanourková Z, Kramer HJ, Husková Z, Vanecková I, Opocenskỳ M, Chábová VC, Tesar V, Skaroupková P, Thumová M, Dohnalová M, Mullins JJ & Cervenka L (2006). AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens 24, 2465-2472.
43. Véniant M, Whitworth CE, Ménard J, Sharp MGF, Gonzales MF, Bruneval P & Mullins JJ (1995). Developmental studies demonstrate age-dependent elevation of renin activity in TGR(mRen2)27 rats. Am J Hypertens 8, 1167-1176.
44. Watanabe T, Morisseau C, Newman JW & Hammock BD (2003). In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea. Drug Metab Dispos 31, 846-853.
45. Wei Y, Lin DH, Kemp R, Yaddanapudi GS, Nasjletti A, Falck JR & Wang WH (2004). Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol 124, 719-727.
46. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC & Kroetz DL (2000). Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87, 992-998.
47. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM & Imig JD (2004). Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 15, 1244-1253.